PMA device
EUFLEXXA (1% Sodium Hyaluronate)
Ferring Pharmaceuticals, Inc. · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Dec 3, 2004, newest Dec 28, 2017Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
10
Naming "EUFLEXXA"
MAUDE reports
789
Brand "EUFLEXXA", since 2015
PubMed studies
24
Mentioning "EUFLEXXA"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EUFLEXXA (1% Sodium Hyaluronate)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- EUFLEXXA (1% Sodium Hyaluronate)PMA supplement
P010029-S025 · Decided Dec 28, 2017 · 191 days after receipt · Normal 180 Day Track No User Fee
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
- EUFLEXXA (1% SODIUM HYALURONATE)PMA supplement
P010029-S008 · Decided Oct 11, 2011 · 925 days after receipt · Panel Track
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
- EUFLEXXAPMA supplement
P010029-S002 · Decided Oct 20, 2005 · 15 days after receipt · Normal 180 Day Track No User Fee
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "EUFLEXXA", any status and sponsor, newest update first.
The Cleveland ClinicAcademic, hospital or other
NCT03459365 · 30 participants · Start Jul 9, 2018 · Primary completion Sep 30, 2021
Device: Euflexxa · For: Osteo Arthritis Knee
Sites: Cleveland, Ohio
- Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OAPivotal-lookingCompleted
Bioventus LLCNot on our public-company list
NCT02110238 · 421 participants · Start Mar 2014 · Primary completion Nov 2014
Device: Supartz; Euflexxa · For: Osteoarthritis
Sites: Durham, North Carolina
University of California, San FranciscoAcademic, hospital or other
NCT01895959 · 12 participants · Start Aug 2013 · Primary completion Nov 2016
Device: Magnetic Resonance Imaging (MRI) · For: Knee Osteoarthritis
Sites: San Francisco, California
7 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EUFLEXXA", and for the whole product code for context.
This brand
789 reports: 8 malfunction, 615 injury, 148 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
- EUFLEXXAInjury
0002244564-2026-00022 · Received Oct 29, 2026 · Event dated Oct 16, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Anaphylactoid / Anaphylaxis
- EUFLEXXAOther
MW6004708 · Received Oct 28, 2026 · Event dated Oct 16, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Anaphylactic Shock; Headache; Itching Sensation; Rash; Dizziness; Low Oxygen Saturation; Confusion/ Disorientation; Skin Inflammation/ Irritation
- EUFLEXXAInjury
0002244564-2026-00021 · Received Oct 26, 2026 · Event dated Jan 1, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Arthralgia; Malaise; Ambulation or Postural Difficulties; Swelling/ Edema
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1635-2010 · Started Apr 16, 2010 · Posted by FDA May 21, 2010
Reason given: Out of Specification results for molecular weight or viscosity through the established expiration date.
Cause as FDA categorized it: Process control · Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Published research
The most relevant PubMed records for "EUFLEXXA"[tiab]. The summary above synthesizes these.
- A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid.
Nicholls M, Manjoo A, Shaw P, et al. · Adv Ther · 2018Research Support, Non-U.S. Gov't
- Potential Impact of Biologically Derived Hyaluronic Acid on Quality of Life in Patients with Knee Osteoarthritis in the United States.
Rosen J, Sancheti P, Fierlinger A, et al. · Adv Ther · 2017
- Biomimetic proteoglycans can molecularly engineer early osteoarthritic cartilage in vivo.
Phillips ER, Prudnikova K, Bui T, et al. · J Orthop Res · 2019Research Support, Non-U.S. Gov't
- Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee.
Rosen J, Sancheti P, Fierlinger A, et al. · Adv Ther · 2016
- Intraarticular Hyaluronic Acid Preparations for Knee Osteoarthritis: Are Some Better Than Others?
Webner D, Huang Y, Hummer CD · Cartilage · 2021Research Support, Non-U.S. Gov't, Review
- Essential elements in synovial fluid samples obtained from patients living in Northern Poland.
Konieczynski P, Szreder G, Tamowska E, et al. · J Trace Elem Med Biol · 2018
- Hyaluronan Injections Show No Histologic Evidence of Adverse Tissue Effects.
Bisogno M, Vojdani S, Aalai M, et al. · Geriatr Orthop Surg Rehabil · 2019
- A Comprehensive Review of Viscosupplementation in Osteoarthritis of the Knee.
Peck J, Slovek A, Miro P, et al. · Orthop Rev (Pavia) · 2021Review
- Risk of Severe Acute Localized Reactions for Different Intraarticular Hyaluronic Acid Knee Injections in a Real-World Setting.
Ong KL, Farr J, Gudeman AS, et al. · Cartilage · 2021Research Support, Non-U.S. Gov't
- Two new intra-articular injections for knee osteoarthritis.
Med Lett Drugs Ther · 2018
- PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ.
Kim DH, Kim DH, Heck BE, et al. · Regen Ther · 2020
- Delay to TKA in Patients Treated with a Multimodal Approach Using High Molecular Weight, Biologically Derived Hyaluronic Acid.
Malanga G, Martins D, Nalmachu S, et al. · J Long Term Eff Med Implants · 2021Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code MOZ.
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
- Orthovisc Sodium HyaluronateAnika Therapeutics, Inc. · PMA 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.